.png){kind=icon}
.png){kind=icon}
Return
Efficacy and tolerability of mirogabalin, pregabalin, duloxetine, and placebo in patients with type 2 diabetes mellitus and painful diabetic peripheral neuropathy: A network meta-analysis
.png){kind=icon}
PRE
AI
A
T
M
H
H
G
M
S
M
M
H
DOI：10.1016/j.diabres.2026.113469.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Duloxetine 120 mg achieved the greatest pain reduction in type-2 diabetes mellitus associated with diabetic neuropathic pain. • Mirogabalin 30 mg was the only agent with significant > 50% responder advantage. • Pregabalin showed modest efficacy but disproportionate adverse effect burden. • Pregabalin 600 mg significantly increased overall adverse effects vs placebo. • Duloxetine demonstrated superior metabolic safety over alpha-2-delta ligands.
Journal
IF:
7.4
Papers:
1.1W
Citations:
2.2W
Organization
Cited Papers